: A potent tubulin inhibitor that kills the cancer cell once the antibody binds to the HER2 receptor and is internalized.

: In the ACE-Breast-02 trial , ARX788 significantly improved progression-free survival (PFS) to 11.3 months compared to 8.2 months for standard treatments.

ARX788 is a site-specific ADC designed to target and HER2-low cancers. Unlike traditional therapies, it uses a unique non-natural amino acid technology to link a potent toxin directly to an antibody, ensuring the "payload" is delivered specifically to cancer cells while sparing healthy tissue. 1. Clinical Applications & Efficacy